Skip to main content
OpenTrials
Completed

NCT Number: NCT00662363

Lubiprostone (Amitiza®) Vs. Standard Care in Opioid-induced Constipation After Surgery in Inpatient Rehabilitation

Patients requiring opioids for post-operative pain control following elective orthopedic procedures which has resulted in constipation symptoms, and who are in inpatient rehabilitation will be randomized to two different treatment arms: lubiprostone or senna. Baseline scores regarding constipation and a quality of life bowel questionnaire will be compared the day following 6 days of treatment intervention.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rehabilitation Institute of Chicago

Chicago, Illinois, 60302, United States

About this study

The purpose of this study is to assess the efficacy of Lubiprostone (Amitiza) compared to standard care for the treatment of constipation in orthopedic patients receiving opioids for pain control during inpatient rehabilitation. Lubiprostone (Amitiza®) is a locally acting chloride channel activator that increases intestinal fluid, and thus increases intestinal motility. It has been approved for chronic constipation, but not in the setting of opioid-induced constipation. Senna is a stimulant laxative that increases propulsive peristaltic activity of the colon through local effects on the mucosa.

Subjects will be compared using from the Patient Assessment of Constipation (PAC) which has previously been found to be a valid and reliable way to measure constipation symptoms and clinical course. (Frank, Kleinman et al. 1999) as well as with other measures of bowel-related symptoms and functional outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult, 18 years old or greater.
  • The patient is able to provide informed consent.
  • Anticipated duration of hospitalization of at least 7 days.
  • Woman of childbearing potential must have a negative serum pregnancy test at enrollment. Exclusions for testing include two years or greater postmenopausal, hysterectomy or tubal ligation.
  • Use of opioid for post-op analgesia following orthopedic surgical procedures as defined as IV, IM, transdermal or PO opioid received within the prior 24 hours of hospitalization for pain control, and expectation that an opioid will be continued for pain control.
  • Medication may be administered on a PRN (as needed) basis or scheduled basis
  • One or greater doses has been received within the 24 hours prior to enrollment as determined by medication administration recorded from the acute care facility or RIC MAR.
  • At least one associated symptom of constipation at the time of admission, such as, but not limited to:
  • Lumpy or Hard stools
  • Feeling of incomplete evacuation of bowels
  • Abdominal cramping or pain
  • Straining with movement of bowels or painful bowel movement effort
  • Need for manual assistance to have a bowel movement

Exclusion criteria

  • Known allergy or sensitivity to the study medications
  • Females who are pregnant
  • Diarrhea on the day of admission
  • Diagnosis of Clostridium difficile infection during the current hospitalization
  • Pre-existing medical condition or surgical procedure, which is known to commonly lead to bowel dysfunction such as, but not limited to:
  • Crohn's disease
  • Ulcerative colitis
  • Multiple sclerosis
  • Cerebral palsy
  • Spinal Cord Injury
  • Colectomy
  • Malabsorption Syndrome
  • Irritable Bowel Syndrome
  • Abdominopelvic neoplasm (gastric, colon cancer)
  • Severe liver disease
  • Colonic or ileo-colonic resections

Treatment and study plan

Lubiprostone

Drug

24 µg po BID given with meals for 6 days

Other names: Amitiza

Senna

Drug

2 tabs daily for 6 days

Other names: Sennasides 8.6 mg each tab

Primary outcomes

  1. Change in Patient Assessment of Constipation (PAC) - Symptoms (Sym)

    Time frame: Baseline and Day 7, after treatment completed (6 days of treatment)

    Patient Assessment of Constipation (PAC) - Change in this measure was assessed. The PAC has previously been found to be a valid and reliable way to measure constipation symptoms and clinical course. The PAC has two components. The symptom (SYM) component is composed of 12 items with score range 0-4 with lower scores indicating improvement. Scores within the two domains were separately averaged. The PAC-SYM questionnaire has shown good concurrent and clinical validity for opioid-induced constipation in a number of pain populations and has demonstrative responsiveness to treatment. There are three symptom domains within the PAC-SYM: Abdominal symptoms (4 items), rectal symptoms (3 items) and stool symptoms (5 items).

  2. Change in Patient Assessment of Constipation - Quality of Life

    Time frame: Baseline and day 7

    The second component of the PAC is the quality of life (QOL) component.The quality of life (QOL) component consists of five items that are rated on a 0-4 scale with higher scores indicating better QOL. Scores within the domains are averaged.

Sponsors and collaborators

Lead sponsor

Shirley Ryan AbilityLab

Other

Collaborators

  • Takeda Pharmaceuticals North America, Inc.

Registry information

Official study title

Lubiprostone (Amitiza®) Compared to Standard Care in the Treatment of Postoperative Opioid-induced Constipation in Inpatient Rehabilitation Patients Following Orthopedic Procedures

Important dates

Study start
2008
Primary completion
2011
Study completion
2011
First posted
Apr 21, 2008
Registry last updated
Mar 6, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.